Article Correctness Is Author's Responsibility: Novel Cell-Based Therapy Induces Cell Death in Sensitive and Resistant Non-Hodgkin Lymphoma Models

Newswise imageInvestigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.